Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sun Sensitivity Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

NCT04147260
View directory record Official record
Conditions
Healthy
Interventions
BI 730357, Placebo to match BI 730357, Ciprofloxacin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Jul 22, 2026, 9:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hats on Head Start: A A Survey of Sun Protection Behaviors in Head Start and Other Early Childhood Education Programs

NCT03199573
View directory record Official record
Conditions
Sunburn
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jul 22, 2026, 9:53 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

NCT04520217
View directory record Official record
Conditions
Photosensitivity, Microvesicle Particle
Interventions
4% Imipramine Cream, Base Cream
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 22, 2026, 9:53 PM EDT
Recruiting Not applicable Interventional

Pilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury

NCT06109909
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Photophobia
Interventions
Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 22, 2026, 9:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

NCT07024316
View directory record Official record
Conditions
Congenital Erythropoietic Porphyria (CEP)
Interventions
ATL-001 (Ciclopirox oral solution)
Drug
Lead sponsor
Atlas Molecular Pharma
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Test for Photo Allergy Reaction of Sunscreens

NCT02872220
View directory record Official record
Conditions
Photoallergy
Interventions
SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pinellas Park, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

NCT03892564
View directory record Official record
Conditions
Phototoxicity
Interventions
MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 22, 2026, 9:53 PM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

NCT00979004
View directory record Official record
Conditions
Epilepsy
Interventions
ICA-105665
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Little Rock, Arkansas • Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

NCT00353158
View directory record Official record
Conditions
Healthy Volunteers, Fungal Infections, Bacterial Infections
Interventions
Doxycycline, Voriconazole
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
8 Years to 100 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 22, 2026, 9:53 PM EDT
Recruiting No phase listed Observational

Natural History Study for DNA Repair Disorders

NCT05484570
View directory record Official record
Conditions
DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions
Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection
Other
Lead sponsor
University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
40 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn

NCT06651476
View directory record Official record
Conditions
Sunburn
Interventions
oxytocin, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

PF-06372865 in Subjects With Photosensitive Epilepsy

NCT02564029
View directory record Official record
Conditions
Reflex Epilepsy, Photosensitive
Interventions
PF-06372865, Placebo, Lorazepam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Boise, Idaho • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 22, 2026, 9:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Helping Children be Safe Outdoors With Sun Protection

NCT02177006
View directory record Official record
Conditions
Sun Sensitivity, Sun Protection, Skin Cancer
Interventions
Sun Protection Program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 22, 2026, 9:53 PM EDT
Not listed No phase listed Observational

Xeroderma Pigmentosum Patient Experiences

NCT01123694
View directory record Official record
Conditions
Xeroderma Pigmentosum
Interventions
Survey Study
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer

NCT04811079
View directory record Official record
Conditions
Photosensitivity
Interventions
419 nm Spectacle Filter, 437 nm Spectacle Filter, 456 nm Spectacle Filter, 476 nm Spectacle Filter, 373 nm Spectacle Filter
Other
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors

NCT03927742
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Shade + app with messaging, Shape + app without messaging
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

NCT04531527
View directory record Official record
Conditions
Dermatitis, Phototoxic
Interventions
Butenafine HCl 1% (BAY1896425)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 22, 2026, 9:53 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer

NCT01522677
View directory record Official record
Conditions
Colon Cancer
Interventions
PDT with 5-ALA radiosensitization
Drug
Lead sponsor
Edward Nelson
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Jul 22, 2026, 9:53 PM EDT
Completed No phase listed Observational

Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy

NCT00001813
View directory record Official record
Conditions
Cockayne Syndrome, Skin Neoplasms, Xeroderma Pigmentosum, Trichothiodystrophy Syndromes, Genodermatosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Weeks to 100 Years
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project Options - The ABC Method

NCT03489356
View directory record Official record
Conditions
Dermatology/Skin - Other, Health Behavior, Sunburn
Interventions
Addressing Behavior Change (ABC)
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Photoallergy Potential of Atralin Gel

NCT00603772
View directory record Official record
Conditions
Healthy
Interventions
Atralin (tretinoin) gel, 0.05%
Drug
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Jul 22, 2026, 9:53 PM EDT
Withdrawn Phase 1 Interventional

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT04500548
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions
Biospecimen Collection, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 9:53 PM EDT